Moderna (NasdaqGS:MRNA) Q4 2025 Earnings call February 13, 2026 08:00 AM ET Company ParticipantsAdi Jayaraman - Senior Managing DirectorElizabeth Webster - Biotech Equity ResearchJamey Mock - CFOLavina Talukdar - Head of Investor RelationsMatthew Guggenbiller - Equity Research AssociateMichael Yee - Global Head of Biotechnology Research and Managing DirectorShelby Hill - Senior Equity Research AssociateStephen Hoge - PresidentStéphane Bancel - CEOConference Call ParticipantsCourtney Breen - Senior AnalystEl ...

Financial Data and Key Metrics Changes - The company reported GAAP earnings of $2.5 million for Q4, with earnings available for distribution (EAD) at approximately -$500,000, leading to a per diluted share of $0.06 [8] - The company has a negative book value of about $300 million, or $31 per diluted share, and a common stock dividend yield of 8.7% [9] - The company holds around $100 million in cash and liquidity, with total equity in the vehicle at $300 million [7] Business Line Data and Key Metrics Changes - The company is focused on acquiring multifamily loans from its operating business, Genesis, which is projected to produce between $6 billion and $7 billion in loans this year [11] - The company aims to grow earnings to between $1.60 and $1.70 per share, contingent on a recapitalization of the vehicle [5][11] Market Data and Key Metrics Changes - The company is currently trading at roughly 50% of its book value, with stock prices fluctuating between $15 and $16 following a 6-to-1 reverse stock split [4][7] - The commercial real estate sector is experiencing dislocation, with many REITs and BDCs trading poorly, which presents potential opportunities for the company [9][10] Company Strategy and Development Direction - The company plans to reposition itself as a dedicated commercial real estate vehicle and an opportunistic investment vehicle, focusing on capital formation and earnings growth [4][5] - The strategy includes acquiring multifamily loans and expanding into commercial real estate investments, with a focus on opportunistic acquisitions [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for earnings growth and the ability to attract third-party capital, while remaining cautious about market conditions [10][29] - The company is committed to maintaining a clean balance sheet and is patient in its approach to recapitalization, aiming to avoid dilutive actions [10][29] Other Important Information - The company has identified a pool of approximately $1 billion in assets that could be added to the vehicle, subject to board approvals, which would lead to an immediate increase in earnings [30] - Management highlighted the importance of credit quality in sourcing loans, emphasizing a balanced approach between internal and third-party loan origination [39][40] Q&A Session Summary Question: Will RPT receive a slice of the NOI from the Paramount transaction? - Management indicated that RPT has $50 million of the Paramount deal on its balance sheet, and earnings will be pro rata based on Rithm's performance [19] Question: Are there plans to explore more loans from Genesis? - Management confirmed that Genesis is expected to produce $6 billion to $7 billion in loans, and successful capital raises would allow for loans to be added directly to the balance sheet, enhancing earnings [20] Question: Is there a tolerance for finding other sources of capital? - Management acknowledged the potential for third-party capital to be introduced, but emphasized the importance of timing and market conditions [28] Question: What types of loans will be prioritized? - Management stated that the primary focus will be on multifamily loans generated by Genesis, which are expected to be highly accretive [30] Question: Is there an opportunity to acquire from banks? - Management noted that there is currently limited bank selling, but the demand for Genesis's products remains strong, creating opportunities for growth [41]

Moderna (NasdaqGS:MRNA) Q4 2025 Earnings call February 13, 2026 08:00 AM ET Company ParticipantsAdi Jayaraman - Senior Managing DirectorElizabeth Webster - Biotech Equity ResearchJamey Mock - CFOLavina Talukdar - Head of Investor RelationsMatthew Guggenbiller - Equity Research AssociateMichael Yee - Global Head of Biotechnology Research and Managing DirectorShelby Hill - Senior Equity Research AssociateStephen Hoge - PresidentStéphane Bancel - CEOConference Call ParticipantsCourtney Breen - Senior AnalystEl ...

Rithm Property Trust (NYSE:RPT) Q4 2025 Earnings call February 13, 2026 08:00 AM ET Company ParticipantsCraig Kucera - Managing Director of Equity ResearchEmma Hoelke - Deputy General CounselHenry Coffey - Managing DirectorMichael Nierenberg - CEOConference Call ParticipantsJason Stewart - Stock AnalystOperatorThank you for standing by. At this time, I would like to welcome everyone to the Rithm Property Trust Fourth Quarter 2025 Earnings Call. All lines have been placed on mute to prevent any background no ...

Advance Auto Parts (NYSE:AAP) Q4 2025 Earnings call February 13, 2026 08:00 AM ET Company ParticipantsBret Jordan - Managing DirectorLavesh Hemnani - VP and Head of Investor RelationsMark Jordan - VP of Equity ResearchRyan Grimsland - EVP and CFOShane O'Kelly - President and CEOConference Call ParticipantsChris Horvers - Senior AnalystSeth Sigman - Managing Director and Senior Equity Research AnalystSimeon Gutman - AnalystZach Fadem - Managing Director and Senior Equity AnalystNone - AnalystOperatorWelcome ...

Cameco (NYSE:CCJ) Q4 2025 Earnings call February 13, 2026 08:00 AM ET Company ParticipantsBrian Lee - Chief Risk OfficerCory Kos - VP of Investor Relations and CommunicationsGrant Isaac - President and COOHeidi Shockey - Senior VP and CFOOrest Wowkodaw - Managing DirectorTim Gitzel - CEOConference Call ParticipantsAlexander Pearce - AnalystCraig Hutchison - Director and Base Metal AnalystLawson Winder - Equity Research AnalystMohamed Sidibe - Equity Research AnalystRalph Profiti - Managing Director and Seni ...

CAE (NYSE:CAE) Q3 2026 Earnings call February 13, 2026 08:00 AM ET Company ParticipantsAndrew Arnovitz - SVP, Investor Relations, and Member of CAE’s Executive Management CommitteeCalin Rovinescu - Executive Chairman of the BoardConstantino Malatesta - Interim CFOKrista Friesen - Executive Director of Equity ResearchKristine Liwag - Executive Director and Head of Aerospace & Defense Equity ResearchMatthew Bromberg - President and CEOSheila Kahyaoglu - Managing DirectorConference Call ParticipantsAnthony Val ...

Beyond Air (NasdaqCM:XAIR) Q3 2026 Earnings call February 13, 2026 08:00 AM ET Company ParticipantsBob Goodman - Chief Commercial OfficerCorey Davis - Managing DirectorDan Moorhead - CFOJason Kolbert - Director of ResearchJustin Walsh - Director of HealthcareMarie Thibault - Managing DirectorMike King - Director of ResearchSteve Lisi - CEOConference Call ParticipantsYale Chen - AnalystOperatorGood morning, and welcome everyone to Beyond Air Financial Results Call for the fiscal quarter ended December 31st, ...

Magna International (NYSE:MGA) Q4 2025 Earnings call February 13, 2026 08:00 AM ET Company ParticipantsBrian Morrison - VP and DirectorJake Coleman - Investment Banking DirectorJames Picariello - Director and Head of US Autos ResearchJoseph Spak - Managing DirectorLouis Tonelli - VP of Investor RelationsPhilip D. Fracassa - EVP and CFOSeetarama Swamy Kotagiri - CEOConference Call ParticipantsColin Langan - Automotive and Mobility AnalystDan Levy - Senior Equity Research AnalystEmmanuel Rosner - Senior Autos ...

Ingersoll Rand (NYSE:IR) Q4 2025 Earnings call February 13, 2026 08:00 AM ET Company ParticipantsDavid Raso - Senior Managing Director and PartnerJeff Sprague - Founder and Managing PartnerMatthew Fort - VP of Investor RelationsNigel Coe - Managing Director and the Head of US Capital Goods Equity ResearchVicente Reynal - Chairman and CEOVik Kini - CFOConference Call ParticipantsAndrew Buscaglia - Senior Analyst for US Industrial TechnologyChris Snyder - Executive Director and Equity Research AnalystJoe O'De ...